Skip to content
Kelonia Therapeutics
-
Eli Lilly to acquire Kelonia Therapeutics in a USD3.25B deal to advance in vivo CAR-T cancer therapies
The agreement also includes potential clinical, regulatory, and commercial milestone payments that could raise the total value to USD7 billion,